Ticker > Company >

Laurus Labs share price

Laurus Labs Ltd.

NSE: LAURUSLABS BSE: 540222 SECTOR: Pharmaceuticals & Drugs  2.83 L   1.89 K   496

889.25
+51.50 (6.15%)
NSE: Today, 04:07 PM

Price Summary

Today's High

₹ 901.5

Today's Low

₹ 828.05

52 Week High

₹ 846

52 Week Low

₹ 417.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

47987.98 Cr.

Enterprise Value

50261.98 Cr.

No. of Shares

53.96 Cr.

P/E

94.18

P/B

10.22

Face Value

₹ 2

Div. Yield

0.14 %

Book Value (TTM)

₹  87.02

CASH

50.64 Cr.

DEBT

2324.64 Cr.

Promoter Holding

27.59 %

EPS (TTM)

₹  9.44

Sales Growth

8.41%

ROE

8.72 %

ROCE

10.44%

Profit Growth

70.04 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Laurus Labs Ltd.

Lasinone Trilawil Prolavir LR Trilavir Mini Myvajra

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year8.41%
3 Year3.49%
5 Year13.28%

Profit Growth

1 Year70.04%
3 Year-20.25%
5 Year7.33%

ROE%

1 Year8.72%
3 Year11.55%
5 Year20.32%

ROCE %

1 Year10.44%
3 Year13.42%
5 Year20.48%

Debt/Equity

0.5123

Price to Cash Flow

88.86

Interest Cover Ratio

3.7651

CFO/PAT (5 Yr. Avg.)

1.17159121624922

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 27.59 2.69
Mar 2025 27.62 2.69
Dec 2024 27.62 2.69
Sep 2024 27.18 0.00
Jun 2024 27.18 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 23.6628477357467% in the last 5 years.
  • The company has a good cash flow management; CFO/PAT stands at 1.17159121624922.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.46757215951611.

 Limitations

  • The company has shown a poor profit growth of -20.2546738551189% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.48806787274689% for the Past 3 years.
  • The company is trading at a high PE of 94.18.
  • The company is trading at a high EV/EBITDA of 41.0727.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1116.93 1184.85 1265.19 1650.01 1432.75
Total Expenditure 955.54 1003.02 1058.91 1255.18 1105.37
Operating Profit 161.39 181.83 206.28 394.83 327.38
Other Income 9.3 11.89 7.12 72.16 21.52
Interest 40.89 44.69 48.02 48.6 43.89
Depreciation 91 90.94 88.66 88.19 93.57
Exceptional Items 0 0 0 0 0
Profit Before Tax 38.8 58.09 76.72 330.2 211.44
Tax 10.02 15.65 19.45 78.3 53.5
Profit After Tax 28.78 42.44 57.27 251.9 157.94
Adjusted EPS (Rs) 0.53 0.79 1.06 4.67 2.93

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 4768.72 4707.04 5773.45 4812.39 5216.98
Total Expenditure 3258.85 3421.84 4291.69 4062.51 4272.65
Operating Profit 1509.87 1285.2 1481.76 749.88 944.33
Other Income 27.32 21.55 15.95 47.42 100.47
Interest 65.92 95.86 145.7 150.82 182.2
Depreciation 196.64 235.48 300.58 345.01 358.79
Exceptional Items 0 0 0 0 0
Profit Before Tax 1274.63 975.41 1051.43 301.47 503.81
Tax 318.52 225.32 291.05 77.77 123.42
Net Profit 956.11 750.09 760.38 223.7 380.39
Adjusted EPS (Rs.) 17.82 13.96 14.12 4.15 7.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 107.32 107.47 107.73 107.79 107.85
Total Reserves 2604.92 3280.74 3949.09 4099.26 4456.1
Borrowings 382.64 549.67 565.49 490.53 414.25
Other N/C liabilities 178.68 236.55 229.33 234.11 446.51
Current liabilities 2696.26 2899.57 2844.09 3545.04 4109.3
Total Liabilities 5969.82 7074 7695.73 8476.73 9534.01
Assets
Net Block 1818.04 2186.23 2884.16 3036.31 2887.5
Capital WIP 324.17 755.03 357.06 155.51 336.24
Intangible WIP 0 0 0 0 0
Investments 318.89 361.72 384.12 634.87 740.22
Loans & Advances 91.84 69.82 132.84 292.11 591.9
Other N/C Assets 30.8 31.16 28.52 31.57 24.11
Current Assets 3386.08 3670.04 3909.03 4326.36 4954.04
Total Assets 5969.82 7074 7695.73 8476.73 9534.01
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1274.63 975.41 1051.43 301.47 503.81
Adjustment 240.43 322.36 442.51 478.32 498.63
Changes in Assets & Liabilities -594.55 -308.46 -344.26 -23.27 -327.99
Tax Paid -226.06 -166.34 -268.13 -97.98 -134.39
Operating Cash Flow 694.45 822.97 881.55 658.54 540.06
Investing Cash Flow -899.68 -836.61 -735.27 -756.74 -591.65
Financing Cash Flow 243.13 15.19 -185.19 139.41 59.32
Net Cash Flow 37.9 1.55 -38.91 41.21 7.73

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 27.18 27.18 27.62 27.62 27.59
chandrakanth chereddi 0.01 0.01 0.01 0.01 0.01
chava narasimha rao 0.02 0.02 0.02 0.02 0.02
chunduru venkata lakshman... 2.49 2.49 2.65 2.65 2.65
hymavathi vantaram 0.04 0.04 0.04 0.04 0.04
kamala kommana 0.02 0.02 0.02 0.02 0.02
krishnaveni vasireddi 0.04 0.04 0.04 0.04 0.04
m/s. leven holdings (repr... 1.24 1.24 1.24 1.24 1.24
m/s. nsn holdings (repres... 23.02 23.02 23.02 23.02 22.99
nagamani thokala 0.02 0.02 0.02 0.02 0.02
narasimha rao suryadevara... 0.03 0.03 0.03 0.03 0.03
rama suryadevara 0.03 0.03 0.03 0.03 0.03
satyanarayana chava - - 0.29 0.29 0.29
sekhar babu chunduru 0.02 0.02 0.02 0.02 0.02
venkata ravi kumar vantar... 0.19 0.19 0.19 0.19 0.19
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 72.82 72.82 72.38 72.38 72.41
akash bhanshali 1.33 1.33 1.33 1.33 1.32
anukar projects private l... 3.24 3.24 3.24 3.24 3.24
barclays wealth trustees ... 1.21 1.14 1.14 1.14 1.61
kotak funds - india midca... 1.33 1.39 1.39 1.16 1.13
life insurance corporatio... 2.70 2.70 2.70 2.70 2.17
new world fund inc 6.50 6.50 6.50 6.50 6.49
sbi arbitrage opportuniti... - - - 1.82 1.64
smallcap world fund, inc 4.09 4.09 4.25 4.25 4.25
dsp arbitrage fund - - - 1.16 -
goldman sachs funds - gol... - - 1.18 1.18 -
vanguard total internatio... - 1.00 1.00 1.02 -
dsp equity opportunities ... - - 1.25 - -
sbi large & midcap fund - 2.53 2.11 - -
amansa holdings private l... 2.21 2.14 - - -
mirae asset elss tax save... 5.24 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit FITCH
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY21
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21
Presentation H1FY24

Company News

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Laurus Labs and its performance over the period of time. Laurus Labs stock price today is Rs 889.25.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Laurus Labs cash from the operating activity was Rs 540.06 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Laurus Labs has a Debt to Equity ratio of 0.5123 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Laurus Labs , the EPS growth was 69.9496 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Laurus Labs has OPM of 18.1010853022247 % which is a good sign for profitability.
     
  • ROE: Laurus Labs have a poor ROE of 8.721 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Laurus Labs is Rs 889.25. One can use valuation calculators of ticker to know if Laurus Labs share price is undervalued or overvalued.
Last Updated on:
Brief about Laurus Labs
X